When and how to treat essential thrombocythemia.
Barbui
Tiziano
T
Finazzi
Guido
G
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000209:etiology; D011799:Quinazolines / Q000627:therapeutic use*; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
D000970:Antineoplastic Agents; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide; D001241:Aspirin; D006918:Hydroxyurea